bluebird bio (BLUE) Shares Down 6.6%
bluebird bio Inc (NASDAQ:BLUE)’s share price dropped 6.6% during mid-day trading on Monday . The stock traded as low as $123.46 and last traded at $124.48. Approximately 564,952 shares traded hands during mid-day trading, an increase of 7% from the average daily volume of 528,871 shares. The stock had previously closed at $133.21.
BLUE has been the topic of several recent research reports. BMO Capital Markets raised their price target on bluebird bio to $194.00 and gave the company an “outperform” rating in a report on Friday, February 22nd. Cowen initiated coverage on bluebird bio in a report on Tuesday, February 26th. They issued an “outperform” rating and a $149.91 price target on the stock. Zacks Investment Research cut bluebird bio from a “hold” rating to a “sell” rating in a report on Monday, February 11th. Svb Leerink cut bluebird bio from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 5th. Finally, BidaskClub cut bluebird bio from a “hold” rating to a “sell” rating in a report on Tuesday, April 23rd. Eleven investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. bluebird bio presently has a consensus rating of “Buy” and a consensus price target of $167.24.
The company has a quick ratio of 9.31, a current ratio of 9.31 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $6.86 billion, a PE ratio of -11.69 and a beta of 2.50.
In other news, insider Jeffrey T. Walsh sold 1,500 shares of bluebird bio stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $139.80, for a total transaction of $209,700.00. Following the transaction, the insider now owns 42,421 shares in the company, valued at approximately $5,930,455.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Davidson sold 4,910 shares of bluebird bio stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $155.77, for a total value of $764,830.70. Following the transaction, the insider now owns 36,526 shares in the company, valued at approximately $5,689,655.02. The disclosure for this sale can be found here. Insiders have sold a total of 31,530 shares of company stock worth $4,710,113 in the last quarter. 3.00% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of bluebird bio by 1.0% during the 4th quarter. FMR LLC now owns 8,204,161 shares of the biotechnology company’s stock valued at $813,853,000 after purchasing an additional 80,474 shares in the last quarter. Vanguard Group Inc raised its position in bluebird bio by 10.1% in the 3rd quarter. Vanguard Group Inc now owns 4,619,413 shares of the biotechnology company’s stock valued at $674,435,000 after buying an additional 422,866 shares during the last quarter. BlackRock Inc. raised its position in bluebird bio by 1.2% in the 4th quarter. BlackRock Inc. now owns 2,986,142 shares of the biotechnology company’s stock valued at $296,223,000 after buying an additional 34,053 shares during the last quarter. OppenheimerFunds Inc. raised its position in bluebird bio by 10.6% in the 1st quarter. OppenheimerFunds Inc. now owns 892,749 shares of the biotechnology company’s stock valued at $140,456,000 after buying an additional 85,420 shares during the last quarter. Finally, First Trust Advisors LP raised its position in bluebird bio by 2.1% in the 1st quarter. First Trust Advisors LP now owns 763,308 shares of the biotechnology company’s stock valued at $120,091,000 after buying an additional 15,379 shares during the last quarter.
bluebird bio Company Profile (NASDAQ:BLUE)
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Read More: Investing in Blue-Chip Stocks
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.